Tesaglitazar ameliorates non-alcoholic fatty liver disease and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient mice

Previous research has demonstrated that the dual PPARα/γ agonist tesaglitazar reduces atherosclerosis in a mouse model of hyperlipidemia by reducing both lipid content and inflammation in the aorta. However, much of the underlying mechanism of tesaglitazar in non-alcoholic fatty liver disease (NAFLD...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: ZHANG, BU-CHUN, LI, WEI-MING, LI, XIAN-KAI, ZHU, MENG-YUN, CHE, WEN-LIANG, XU, YA-WEI
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2012
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3494130/
https://ncbi.nlm.nih.gov/pubmed/23226761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2012.713
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky